Myriad RBM Joins Institut Pasteur in the Global Fight Against Tuberculosis
January 20 2015 - 7:05AM
Myriad RBM, a wholly owned subsidiary of Myriad Genetics, Inc.
(Nasdaq:MYGN), today announced that it will assist the Institut
Pasteur in a public-private research collaboration to fight the
global tuberculosis (TB) epidemic. This research project is funded
by the Bill & Melinda Gates Foundation through a grant to the
Institut Pasteur.
The proof-of-concept study will evaluate patients with latent
and active TB infections who are affiliated with the South African
Tuberculosis Vaccine Initiative (SATVI) clinical study sites. The
goals of this study are to field-test Myriad RBM's TruCulture®
system as a point-of-care blood collection and immune response
monitoring method and to stratify patients with active and latent
tuberculosis.
"Tuberculosis is a challenging disease. We need better
technology to diagnose patients and assess individual immune
response to treatment," said Matthew Albert, co-coordinator of
Milieu Interieur and director of the Immunology Department at
Institut Pasteur. "Prior studies support the use of the
TruCulture system in settings with limited resources, and may help
us improve the diagnosis of TB and accelerate the development of
new drugs and vaccines to treat the disease."
Myriad RBM will supply the study with its revolutionary
TruCulture collection systems. Once the blood samples are
collected, Myriad RBM and the Institut Pasteur will seek to
discover protein biomarkers important in regulating the immune
system response using Myriad RBM's proprietary MAP (Multi-Analyte
Profiling) platform.
"We are excited to collaborate with the Institut Pasteur on this
important Gates Foundation-funded research program. We believe
that TruCulture can help to stratify TB patients with latent versus
active disease. This will lead to the optimization of
treatments and provide better support for vaccine clinical trials,"
said Ralph McDade, president of Myriad RBM. "If we are
successful, TruCulture may prove to be useful in a multitude of
field-based, point-of-care applications, leading to improved
patient care."
About Myriad RBM
Myriad RBM is a wholly owned subsidiary of Myriad Genetics,
Inc. Its biomarker discovery platform provides clinical
researchers and healthcare providers with reproducible,
quantitative, multiplexed data for hundreds of proteins to advance
drug development and patient care. The Company's proprietary Multi
Analyte Profiling (MAP) technology offers preclinical and clinical
researchers with broad, cost-effective analyses of multiple
proteins from a single, small sample volume. MAP technology
also supports Myriad RBM's drive to develop companion diagnostics
in areas of unmet medical need such as neuropsychiatry, nephrology
and immunology. More information about Myriad RBM can be
found at www.myriadrbm.com.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company
dedicated to making a difference in patients' lives through the
discovery and commercialization of transformative tests to assess a
person's risk of developing disease, guide treatment decisions and
assess risk of disease progression and recurrence. Myriad is
focused on strategic directives to grow our markets, introduce new
products, including companion diagnostics, as well as to expand
internationally. For more information on how Myriad is making a
difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan Lung
Cancer, BRACAnalysis CDx, Tumor BRACAnalysis CDx, HRD, Vectra and
Prolaris are trademarks or registered trademarks of Myriad
Genetics, Inc. in the United States and foreign countries. MYGN-F,
MYGN-G
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the results of the project
with the Institute Pasture potentially leading to the development
of novel diagnostics and companion diagnostics; the current
findings leading to additional studies and possibly new diagnostic
tests for tuberculosis and other diseases, as well as companion
diagnostics for therapeutics; insights such as those gained in the
current study helping to explain susceptibility to a specific
disease or to predict response to immune-modulating therapies; the
TruCulture system's effectiveness for monitoring the immune
response; developing TruCulture as a novel diagnostic for vaccine
response; and the Company's strategic directives under the caption
"About Myriad Genetics." These risks and uncertainties
include, but are not limited to: the risk that sales and profit
margins of our molecular diagnostic tests and pharmaceutical and
clinical services may decline or will not continue to increase at
historical rates; risks related to our ability to transition from
our existing product portfolio to our new tests, including
unexpected costs and delays; risks related to changes in the
governmental or private insurers reimbursement levels for our tests
or our ability to obtain reimbursement for our new tests at
comparable levels to our existing tests; risks related to increased
competition and the development of new competing tests and
services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services and any future tests and services are terminated
or cannot be maintained on satisfactory terms; risks related to
delays or other problems with operating our laboratory testing
facilities; risks related to public concern over our genetic
testing in general or our tests in particular; risks related to
regulatory requirements or enforcement in the United States and
foreign countries and changes in the structure of the healthcare
system or healthcare payment systems; risks related to our ability
to obtain new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire; risks related to our projections about our business,
results of operations and financial condition; risks related to the
potential market opportunity for our products and services; the
risk that we or our licensors may be unable to protect or that
third parties will infringe the proprietary technologies underlying
our tests; the risk of patent-infringement claims or challenges to
the validity of our patents or other intellectual property; risks
related to changes in intellectual property laws covering our
molecular diagnostic tests and pharmaceutical and clinical services
and patents or enforcement in the United States and foreign
countries, such as the Supreme Court decision in the lawsuit
brought against us by the Association for Molecular Pathology et
al; risks of new, changing and competitive technologies and
regulations in the United States and internationally; and other
factors discussed under the heading "Risk Factors" contained in
Item 1A of our Annual Report on Form 10-K for the fiscal year ended
June 30, 2014, which has been filed with the Securities and
Exchange Commission, as well as any updates to those risk factors
filed from time to time in our Quarterly Reports on Form 10-Q or
Current Reports on Form 8-K.
CONTACT: Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024